Multi-Companion Profiling Assay Enters FDA, CMS Express Lanes

The FoundationOne assay has been accepted into FDA's Expedited Access Pathway and the FDA/CMS Parallel Review program in an effort to advance what would be the first assay approved as a companion diagnostic for a range of tumor targets and drugs at once.

[Editor's note: Check out Medtech Insight's Expedited Access tracker for a running list of devices accepted into the EAP program.]

Foundation Medicine Inc. is taking advantage of two nascent US market pathways to benefit the development of what would...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Regulation

More from Policy & Regulation